[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"short-bowel-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:short-bowel-syndrome":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,42,71,92,124,147,173,194,218,247,273,680],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100590890","phase-3-a-study-of-teduglutide-in-chinese-adults-with-short-bowel-syndrome-100590890",false,"NCT06973304","A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome","An Open-label, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of 0.05 mg\u002Fkg\u002FDay Subcutaneous Teduglutide Following Treatment of Short Bowel Syndrome for 24 Weeks in Chinese Adults Who Are Dependent on Parenteral Support","Inclusion Criteria:\n\n1. Males or females 18 years of age or older at the time of signing the informed consent.\n2. Intestinal failure due to SBS as a consequence of major intestinal resection (example, due to injury, volvulus, vascular disease, cancer, Crohn's disease).\n3. Has undergone intestinal resection resulting in at least 12 continuous months of PS dependency prior to signing the informed consent.\n4. Requires PS at least 3 times per week or at least 4 liters per week during the 2 weeks prior to baseline to meet caloric, fluid, or electrolyte needs due to ongoing malabsorption.\n5. Has a stable PS requirement for at least 4 consecutive weeks immediately prior to the start of teduglutide treatment. Stability is defined as follows:\n\n   1. Actual PS usage is similar to prescribed PS.\n   2. Baseline (Visit 2) 48-hour intake (I)\u002Foutput (O) volumes should fall within +-25% of the respective 48-hour I\u002FO volumes at the last optimization visit.\n   3. The 48-hour urine output volume must not be less than 2 liters and should not exceed 4 liters at the last optimization visit, the stabilization visit, and the baseline visit.\n6. Participants with a history of Crohn's disease must be in endoscopic remission for at least 12 weeks prior to the baseline visit.\n\nExclusion Criteria:\n\n1. Pregnant or lactating female.\n2. Participation in a clinical study using an experimental drug within 30 days or 5 half-lives, whichever is longer, prior to screening, or concurrent participation in any other clinical study.\n3. Use of glucagon-like peptide (GLP)-2 or human growth hormone or analogs of these hormones within the past 6 months prior to the baseline visit.\n4. Use of octreotide, GLP-1 analogs, or dipeptidyl peptidase-4 inhibitors within 30 days prior to the baseline visit.\n5. Previous use of teduglutide.\n6. Active inflammatory bowel disease (IBD) or any participant with IBD requiring immunosuppressant therapy (example, azathioprine,anti-tumor necrosis factor \\[anti-TNF\\]) drugs) that had been introduced or changed within the past 6 months prior to the baseline visit.\n7. Intestinal malabsorption due to a genetic condition, such as cystic fibrosis, microvillus inclusion disease, familial adenomatous polyposis.\n8. Chronic intestinal pseudo-obstruction or severe dysmotility.\n9. Clinically significant intestinal stenosis or obstruction, or evidence of such on upper gastrointestinal (UGI)\u002Fsmall bowel follow-through (SBFT), within the past 6 months prior to the baseline visit.\n10. Major gastrointestinal (GI) surgical intervention, including significant intestinal resection, within the past 3 months (insertion of feeding tube, anastomotic ulcer repair, minor intestinal resections less than or equal to \\[\\\u003C=\\] 10 centimeter \\[cm\\], or endoscopic procedure is allowed) prior to the baseline visit.\n11. Unstable cardiac disease, (example, congestive heart failure, cyanotic disease, or congenital heart disease).\n12. Moderate or severe renal impairment, defined as creatinine clearance less than 50 milliliters per minute (mL\u002Fmin).\n13. Currently diagnosed with cancer or a history of any cancer except surgically cured skin cancer within the past 5 years.\n14. Severe hepatobiliary disease including any of the following:\n\n    1. Total bilirubin level at least 2 times the upper limit of normal (ULN), except for increased indirect (unconjugated) bilirubin in a patient with Gilbert's syndrome.\n    2. AST at least 5\\*ULN.\n    3. ALT at least 5\\*ULN\n15. Active clinically significant pancreatic disease, including clinical signs of pancreatitis associated with elevations in serum amylase or lipase at least 2\\*ULN.\n16. More than 4 SBS-related or PS-related hospital admissions (example, central line-associated bloodstream infection, bowel obstruction, severe fluid\u002Felectrolyte disturbances) within the past 12 months prior to the baseline visit.\n17. Unscheduled hospitalization within 30 days prior to screening.\n18. Non-herpetic viral diseases:\n\n    1. Presence of hepatitis C virus (HCV) antibody and a positive confirmatory test result for HCV RNA (ribonucleic acid) (nucleic acid test or polymerase chain reaction).\n    2. Presence of (Hepatitis B Surface Antigen Positive \\[HBsAg+\\]). For participants who are negative for HBsAg but are positive for either surface antibodies and\u002For core antibodies, hepatitis B virus (HBV) deoxyribonucleic acid (DNA) polymerase chain reaction will be performed; if any test result meets or exceeds detection sensitivity, the subject will be excluded.\n    3. Positive results for human immunodeficiency virus (HIV) by serology, regardless of viral load.\n19. Any condition, disease, illness, or circumstance that in the investigator's opinion puts the participant at any undue risk, prevents completion of the study, or interferes with analysis of the study results. Example of potential disease state\u002Fillnesses that may be excluded are listed in the protocol.","ALL","18 Years",{"count":19,"type":20},13,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The main aim of the study is to assess how well teduglutide works over 24 weeks in Chinese adult participants with short bowel syndrome (SBS) who need parenteral support and to see how much it can reduce the amount of parenteral support and understand how the body absorbs, processes, and gets rid of teduglutide.\n\nParticipants will receive a daily injection of teduglutide under the skin for 24 weeks. Safety of teduglutide will be checked for 24 weeks after treatment.\n\nParticipants will be in the study for about 65 weeks.",[26],"Short Bowel Syndrome",[28],"Drug Therapy","RECRUITING","2026-06-19",{"date":32,"type":33},"2026-06-24","ACTUAL",{"date":35,"type":33},"2025-06-26",{"date":37,"type":20},"2027-07-28",{"name":39,"class":40},"Takeda","INDUSTRY",4,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100585631","phase-2-safety-and-efficacy-of-crofelemer-in-adult-patients-with-short-bowel-syndrome-and-intestinal-failure-sbs-if-without-colon-in-continuity-cic-100585631","NCT06904872","Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)","A Phase 2, Placebo-Controlled, Randomized, Double-Blind Study of 2 Doses of Crofelemer for the Treatment of Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)","CRO-SBS-IF","Inclusion Criteria\n\nPatients will be enrolled in the study if they meet all the following criteria:\n\n1. Patients must understand and provide written informed consent before they can participate in the study. They must understand the study procedures and be willing to complete the required assessments;\n2. Male and female patients aged ≥ 18 years;\n3. SBS patients with intestinal failure and without colon-in-continuity who are not eligible or not willing to receive an approved marketed GLP-2;\n4. Patients with history of SBS resulting in intestinal failure caused by a major intestinal resection (e.g., injury, cancer\\*, Crohn's disease, vascular disease, volvulus) without colon-in-continuity (patients with duodenostomy, Jejunostomy or Ileostomy). Intestinal failure will be defined according to the recommendations of the European Society for Clinical Nutrition and Metabolism (ESPEN), i.e., a reduction of gut function below the minimum necessary for the absorption of macronutrients and\u002For water and electrolytes, such that intravenous (IV) supplementation is required to maintain health and\u002For growth. \\*Patients with history of cancer, should be in remission for the last 6 months and with not ongoing anticancer therapy (long-term hormonal therapy is allowed).\n5. Minimum remaining length of 60 cm of small bowel;\n6. At least 6 months elapsed since last surgical bowel resection;\n7. No restorative surgery planned during the entire study period;\n8. Patients with at least 4 continuous months of PS dependency (parenteral nutrition with or without intravenous fluids);\n9. Chronic non-infectious diarrhoea defined as passage of at least 1 loose watery stool per day for more than 4 consecutive weeks.\n10. Patients receiving parenteral support (fluids, electrolytes and\u002For nutrients) for at least three days per week and a minimum of 6 liters of PS per week, to meet caloric, fluid or electrolytes needs;\n11. Patients with Crohn's disease will have to be in clinical remission for ≥ 12 weeks;\n12. Patients must be able to ingest solid or semi-solid foods and drink fluids;\n13. If taken at screening, use of antimotility and antidiarrheal agents (loperamide, diphenoxylate, codeine and other opiates), H2-receptor antagonists, proton pump inhibitors, bile sequestering agents, oral glutamine, diuretics and oral rehydration solutions is required to be at stable average weekly doses for at least 4 weeks prior to screening evaluations;\n14. If female and of child-bearing potential, the patient must use an \"acceptable effective contraceptive measure\" for the entire study duration and for 4 weeks after the last dose. Acceptable birth control methods that result in a failure rate of more than 1% per year include: progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action male or female condom with or without spermicide cap, diaphragm or sponge with spermicide (A combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods) are also considered acceptable). Male patients must agree to use an acceptable form of birth control and to not donate sperm during the study and for 4 weeks after the last dose.\n15. If female and child-bearing potential, the patient must have a negative urine pregnancy test prior the first administration of the investigational product;\n16. Satisfactory general health status as determined by the investigator based on current medical status, medical history and physical examination.\n\nExclusion criteria\n\nPatients cannot be enrolled in the study if they meet any of the following criteria:\n\n1. Diagnosis of celiac disease or active or refractory tropical sprue;\n2. Presence of clinically significant intestinal adhesions and\u002For chronic abdominal pain that can interfere with the conduct of the study;\n3. Patients with current radiological (Radiography and\u002For CT) evidence of bowel dilatation or pseudo-obstruction;\n4. Active Crohn's disease as evaluated by standard procedures employed by the investigator;\n5. Inflammatory bowel disease (IBD) that required immunosuppressant therapy that has been introduced or changed within last 3 months or treatment with biologics within the last 6 months;\n6. Intestinal or other major surgery scheduled within the time frame of the study;\n7. Visible blood in the stool within the last 12 weeks;\n8. Clinical evidence of active radiation enteritis or scleroderma, contributing to the patient's stool volume;\n9. Compromised immune system (e.g., acquired immune deficiency syndrome \\[AIDS\\], severe combined immunodeficiency);\n10. Inadequate hepatic function: alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) and\u002For total bilirubin and\u002For alkaline phosphatases \\> 2 times the patient's average relative values in the last 3 months;\n11. Inadequate renal function: serum creatinine or blood urea nitrogen \\> 2 times the Upper Normal Limit (UNL);\n12. Urine sodium \\\u003C20 mmol\u002Fday;\n13. More than four SBS-related hospital admissions (unless one or more admissions were to rule out line sepsis) within the past 12 months or hospital admission within the last 4 weeks;\n14. Concurrent or past use of infliximab, growth hormone or growth factors such as native glucagon-like peptide-2 (GLP-2) or other biological therapy within the last 12 weeks;\n15. Use of systemic corticosteroids, methotrexate, cyclosporine, tacrolimus, sirolimus, octreotide, intravenous glutamine within the last 4 weeks;\n16. Use of antibiotics within the last week or active infection;\n17. History of alcohol abuse (Drinking more than 12 g\u002Fday of alcohol for women and 24 g\u002Fday of alcohol for men) or drug abuse within the last year;\n18. Pregnant or lactating women;\n19. History of psychiatric illnesses which lead to consider the patient as incapacitated and prevent him\u002Fher to provide informed consent;\n20. History of any other uncontrolled chronic or acute concomitant disease which, in the Investigator's opinion, would contraindicate study participation or confound interpretation of the results;\n21. Patient not capable of understanding or not willing to adhere to the study visit schedules and other protocol requirements;\n22. Participation in any other interventional clinical study within five times the half-life of the investigational medicinal product \u002F relevant metabolites (of the previous clinical study) or 4 weeks (whichever is longer) prior to screening;\n23. Known hypersensitivity\u002Fallergy to ANY component of the IP.",{"count":51,"type":20},18,[53],"PHASE2","A 24-week, randomized, placebo-controlled, double-blind study to evaluate the efficacy, safety and tolerability of crofelemer in patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF) without colon-in-continuity (CIC) requiring parenteral support (PS).\n\nBlinded study drug will be administered orally (or enterally) three times daily (TID) as a novel crofelemer formulation, Crofelemer Powder for Oral Solution, or a matching placebo powder formulation for oral solution.\n\nPatients will be randomized in a 1:1:1 ratio to crofelemer 3 mg\u002Fkg\u002Fdose TID, crofelemer 10 mg\u002Fkg\u002Fdose TID or placebo.",[26,56,57,58,59],"Malabsorption Syndromes","Short Gut Syndrome","Post-Op Complication","Functional Gastrointestinal Disorders",[26],"2026-06-05",{"date":63,"type":33},"2026-06-09",{"date":65,"type":33},"2025-05-29",{"date":67,"type":20},"2027-03",{"name":69,"class":40},"Napo Therapeutics, S.p.A.",8,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":91},"100422044","phase-2-phase-2-study-to-assess-the-safety-pk-and-pd-of-sonefpeglutide-hm15912-in-sbs-if-subjects-100422044","NCT04775706","Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects","A Multicenter, Proof-of-concept, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15912 (Sonefpeglutide) in Adult Subjects With Short Bowel Syndrome-associated Intestinal Failure (SBS-IF)","Inclusion Criteria:\n\n1. Men or women, aged 18 years of age or older with SBS resulting in intestinal failure at the time of signing the informed consent form (ICF) (or country's legal age of majority if the legal age is \\\u003C18 years)\n2. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol\n3. Diagnosis of SBS with the latest intestinal resection being at least 6 months prior to Screening and considered stable regarding the PN\u002FIV need. No restorative surgery planned in the study period.\n\nExclusion Criteria:\n\n1. Any history of colon cancer.\n2. History of any other cancers (except margin-free resected cutaneous basal or squamous cell carcinoma or adequately treated in situ cervical cancer) unless disease-free for at least 5 years\n3. History of alcohol or drug abuse (within 1 year of screening)",{"count":51,"type":20},[53],"This is a randomized, double-blind, placebo-controlled, proof-of-concept (PoC), Phase 2 study to assess the safety, PK, and PD of SC administration of HM15912(sonefpeglutide) in adult subjects with SBS-associated intestinal failure (SBS-IF).",[26],"2026-04-26",{"date":84,"type":33},"2026-04-28",{"date":86,"type":33},"2022-03-03",{"date":88,"type":20},"2028-05",{"name":90,"class":40},"Hanmi Pharmaceutical Company Limited",14,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":104,"conditions":105,"keywords":106,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100608160","phase-3-efficacy-and-safety-evaluation-of-glepaglutide-in-treatment-of-sbs-100608160","NCT07197944","Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS","A Phase 3, Double-blind, Randomized, Parallel Group, Placebo-controlled, Multicenter Trial to Confirm the Efficacy and Safety of Glepaglutide 10 mg Twice Weekly, Followed by a Long-term, Open-label Safety Evaluation in Patients With Short Bowel Syndrome-intestinal Failure (SBS-IF)","EASE SBS 5","Key Inclusion Criteria:\n\n* Signed informed consent;\n* Age of 18 to 90 years;\n* A diagnosis of SBS, defined as having a small bowel with an estimated length of less than 200 cm (equal to 79 inches) in continuity (latest intestinal resection ≥6 months before screening);\n* Stable PS need of ≥3 days per week;\n* No restorative surgery planned during the trial period;\n* Having a stoma or colon in continuity.\n\nKey Exclusion Criteria:\n\n* More than 2 SBS- or PS-related hospitalizations within 6 months before screening;\n* Poorly controlled Inflammatory Bowel Disease (IBD) that is moderately or severely active or a fistula that can interfere with the measurements or examinations required in the trial;\n* History of colorectal cancer or any other type of cancer (except for margin-free resected cutaneous basal, squamous cell carcinoma or adequately treated in situ cervical cancer) unless the patient has been disease-free for at least 5 years; ongoing bowel obstruction;\n* BMI \\\u003C18.5 kg\u002Fm\\^2.","90 Years",{"count":102,"type":20},90,[23],"The purpose of the present Phase 3 trial is to confirm the efficacy and safety of glepaglutide 10 mg twice weekly in a patient population with SBS-IF and generate additional long-term safety data.\n\nGlepaglutide is the International Nonproprietary Name and United States Adopted Name (USAN) for ZP1848.",[26],[107,108,56,109,110,111,112,26,113],"Intestinal Failure","Pathologic Processes","Intestinal Diseases","Gastrointestinal Diseases","Digestive System Diseases","Postoperative Complications","Syndrome","2026-04-17",{"date":116,"type":33},"2026-04-20",{"date":118,"type":33},"2026-02-11",{"date":120,"type":20},"2032-02-28",{"name":122,"class":40},"Zealand Pharma",23,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":131,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":70},"100555476","phase-3-efficacy-and-safety-of-pj009-in-patients-with-short-bowel-syndrome-requiring-parenteral-nutrition-100555476","NCT06512584","Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition","Inclusion Criteria:\n\n1. Male and female aged ≥ 14 years;\n2. SBS patients dependent on PN\u002FIV support for at least 6 consecutive months due to major intestinal resection;\n3. At least 3 PN\u002FIV support sessions per week are required 1 week before screening or 2 weeks before baseline;\n4. Be on stable PN\u002FIV support for at least 4 consecutive weeks before administration;\n5. For subjects with a history of Crohn's disease (CD), clinical assessment of remission for at least 12 weeks prior to administration;\n6. Be able to understand and provide signed informed consent, for those under 18 years old, the guardian should also sign the informed consent;\n7. Be able to complete experiments in accordance with the protocol.\n\nExclusion Criteria:\n\n1. Have used teduglutide in the past or may be allergic to teduglutide or its components;\n2. Have used natural GLP-2 or its analogs, human growth hormone or its analogs within 6 months before screening;\n3. Have used glutamine, octreotide, GLP-1 analogs or dipeptidyl peptidase-IV inhibitors within 30 days before screening;\n4. With active Crohn's disease or those who need to change biological therapy within 6 months before screening;\n5. With active inflammatory bowel disease (IBD) or IBD patients who have received immunosuppressant therapy changes in the past 3 months;\n6. With unstable absorption due to cystic fibrosis, untreated megacolon disease or known DNA abnormalities (such as familial adenomatous polyposis, Fanconi syndrome);\n7. With clinically obvious intestinal obstruction or active stenosis within 6 months before screening;\n8. Have undergone major gastrointestinal surgical intervention within 3 months before screening, such as continuous transverse enteroplasty or other intestinal lengthening surgery (esophageal intubation or endoscopic surgery is allowed);\n9. Severe active, uncontrolled, untreated systemic diseases (such as cardiovascular, respiratory, renal, infectious, endocrine, liver or central nervous system diseases, etc.);\n10. Have malignant tumors within 5 years before screening (except for fully treated cervical carcinoma in situ, basal cell or squamous cell carcinoma of the skin, localized prostate cancer after radical surgery, and breast ductal carcinoma in situ after radical surgery);\n11. With severe liver function impairment:\n\n    1. Total bilirubin ≥ 2.0 × upper limit of normal (ULN); for patients with Gilbert's syndrome, direct bilirubin ≥ 2.0 × ULN;\n    2. Aspartate transaminase (AST) ≥ 5.0 × ULN, alanine transaminase (ALT) ≥5.0 × ULN;\n12. With renal function impairment:\n\n    1. Serum creatinine ≥2.0 × ULN;\n    2. Creatinine clearance \\\u003C 60 ml\u002Fmin (calculated according to the Cockcroft-Gault formula, see Appendix 3 for details);\n13. Pancreatic abnormalities:\n\n    1. Serum amylase ≥ 2.0 × ULN;\n    2. Serum lipase ≥ 2.0 × ULN;\n14. More than 4 SBS or PN-related hospitalizations (such as catheter sepsis, intestinal obstruction, severe water and electrolyte disorders) within 12 months before screening;\n15. Unplanned hospitalization within 30 days before screening;\n16. Pregnant or lactating women, women or men who have fertility plans or do not agree to take effective contraceptive measures during the trial;\n17. Participated in any clinical trial (excluding antibody treatment-related clinical trials) within 30 days before screening or participated in any antibody treatment-related clinical trials within 3 months before screening;\n18. Other condition the investigator believes would be unsuitable for participation in this clinical study.","14 Years",{"count":133,"type":20},72,[23],"The main aim of this clinical trial is to assess the efficacy and safety of PJ009 in patients aged ≥14 with short bowel syndrome (SBS) requiring parenteral nutrition. The main questions it aims to answer are:\n\n* How effective is PJ009 in treating short bowel syndrome?\n* Is PJ009 safe in these patients? Researchers will compare PJ009 to a placebo (a look-alike substance that contains no drug) to see if PJ009 works to treat SBS.\n\nParticipants will\n\n* Receive daily subcutaneous injections of PJ009 or placebo according to weight for 24 weeks, and then the participants receive placebo will be switched to receive PJ009 for another 12 weeks, while participants receive PJ009 continued the same treatment until the end of 36 weeks,\n* Visit the clinic at the end of week 1(w1), w2, w4, w8, w12, w16, w20, w24, w30 and w36 for assessment,\n* Keep a diary of the amount of their parenteral nutrition\u002F intravenous fluids (PN\u002FIV), enteral nutrition and urine volume.",[26],[26],"2026-02-26",{"date":140,"type":33},"2026-03-02",{"date":142,"type":33},"2024-09-03",{"date":144,"type":20},"2026-04-27",{"name":146,"class":40},"Chongqing Peg-Bio Biopharm Co., Ltd.",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":158,"conditions":159,"keywords":160,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":172},"100575378","sbs-disk--creation-of-a-quality-of-life-tool-for-short-bowel-patients-compared-with-a-validated-quality-of-life-questionnaire-sbs-qol-100575378","NCT06771505","SBS DISK- Creation of a Quality of Life Tool for Short Bowel Patients Compared With a Validated Quality of Life Questionnaire (SBS QoL)","SBS DISK","Inclusion Criteria:\n\n* Age 18 or over\n* Patient able to read and speak French\n* Patient suffering from short bowel syndrome\n\nExclusion Criteria:\n\n* Known cognitive disorders","99 Years",{"count":156,"type":20},100,"OBSERVATIONAL","Patients with short bowel syndrome have an impact on their quality of life because they need temporary or permanent parenteral nutritional support. The quality of life of these patients has been the subject of several studies and assessment tools exist, such as the Short Bowel Syndrome Quality of Life (SBS QoL). This tool may seem complex and tedious to use in everyday practice. However, it is important to regularly assess the quality of life of these patients. This is why the investigators are proposing to create a new tool for more rapid assessment of the quality of life of patients with short bowel syndrome.",[26],[161,162],"Short Bowel syndrome","Quality of life",{"date":164,"type":33},"2026-02-12",{"date":166,"type":33},"2025-01-15",{"date":168,"type":20},"2027-01-01",{"name":170,"class":171},"Hospices Civils de Lyon","OTHER",1,{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":21,"phases":181,"briefSummary":183,"conditions":184,"keywords":185,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":187,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":172},"100541191","early-phase-1-open-label-pilot-study-with-crofelemer-in-patients-with-short-bowel-syndrome-100541191","NCT06326645","Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome","Inclusion Criteria:\n\n1. Patients must understand and provide written informed consent before they can participate in the study. They must understand the study procedures of the trial and be willing to complete the required assessments;\n2. Male and female patients aged ≥ 18 years;\n3. SBS patients without colon in continuity:\n4. Patients with history of SBS resulting in intestinal failure caused by a major intestinal resection (e.g., injury, cancer, Crohn's disease, vascular disease, volvulus, intussusceptions or other causes). Diagnosis of SBS will be defined as remaining small bowel excluding colon in continuity and considered stable with regard to parenteral support (PS) need. Intestinal failure will be defined according to the recommendations of the American Society of Parenteral and Enteral Nutrition (ASPEN), i.e. a reduction of gut function below the minimum necessary for the absorption of macronutrients and\u002For water and electrolytes, such that intravenous (IV) supplementation is required to maintain health and\u002For growth;\n5. At least 6 months elapsed since last surgical bowel resection;\n6. No restorative surgery planned in the overall study period;\n7. Patients with at least 6 continuous months of PS dependency (parenteral nutrition and\u002For intravenous fluids) before entry in the study;\n8. Patients receiving stable PS (fluids, electrolytes or nutrients) at least three times per week to meet caloric, fluid or electrolytes needs with no major changes in provisions for at least 12 weeks;\n9. Patients with Crohn's disease will have to be in clinical remission for ≥ 12 weeks before entry in the study;\n10. Patients must be able to ingest solid or semi-solid foods and drink fluids;\n11. If female and of child-bearing potential, the patient use a highly effective method of birth control for the entire study duration. Highly effective birth control methods include: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable); intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomized partner; sexual abstinence;\n12. If female and of child-bearing potential, the patient must have a negative urine pregnancy test prior the first administration of the study drugs;\n13. Male patients must agree to use an acceptable form of birth control during the study and for 30 days after the last dose;\n14. Satisfactory general health status as determined by the investigator based on medical history and physical examination\n\nExclusion Criteria:\n\n1. Body mass index (BMI) \\\u003C17.5 or \\>30 kg\u002Fm2;\n2. Presence of clinically significant intestinal adhesions and\u002For chronic abdominal pain that can interfere with the conduct of the study;\n3. Presence of confirmed active infection, temperatures \\>100°Farenheit, or symptoms of an upper respiratory infection\n4. Patients with Radiological (Radiography and\u002For CT) signs of significant bowel dilatation or pseudo-obstruction;\n5. Active Crohn's disease as evaluated by standard procedures employed by the investigator;\n6. Inflammatory bowel disease (IBD) that required immunosuppressant therapy that has been introduced or changed within last 3 months or treatment with biologics within the last 6 months;\n7. Intestinal or other major surgery scheduled within the time frame of the study;\n8. Visible blood in the stool within the last 3 months;\n9. Ongoing radiation enteritis or the presence of damaged enteral tissue due to radiation enteritis, scleroderma, celiac disease, refractory or tropical sprue;\n10. Compromised immune system (e.g., acquired immune deficiency syndrome \\[AIDS\\], severe combined immunodeficiency);\n11. Inadequate hepatic function: alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\>2 upper limit of normal (ULN), total bilirubin \\>1.25 ULN or alkaline phosphatases \\>2.5 ULN;\n12. Inadequate renal function: serum creatinine or blood urea nitrogen \\>1.5 ULN;\n13. Urine sodium \\\u003C20 mmol\u002Fday;\n14. More than four SBS-related hospital admissions (unless one or more admissions were to rule out line sepsis) within the past 12 months or hospital admission within 1 month before screening;\n15. Previous use of Crofelemer or potential allergies to Crofelemer or its constituents;\n16. Use of infliximab, growth hormone or growth factors such as native glucagon-like peptide-2 (GLP-2) or other biological therapy within the last 12 weeks;\n17. Current or past use of teduglutide within the last 3 months;\n18. Use of systemic corticosteroids, methotrexate, cyclosporine, tacrolimus, sirolimus, octreotide, intravenous glutamine within the last 30 days;\n19. If taken at screening, use of antimotility and antidiarrheal agents (loperamide, difenoxylate, codeine and other opiates), H2-receptor antagonists, proton pump inhibitors, bile sequestering agents, oral glutamine, diuretics and oral rehydration solutions is required to be at stable average weekly doses for at least 4 weeks prior to screening evaluations and to remain stable for the entire study duration;\n20. Use of antibiotics within the last 30 days unless they were administered while ruling out line sepsis or for a dental procedure;\n21. Alcohol or drug abuse within the last year;\n22. Pregnant or lactating women;\n23. History of any malignancy in the past 1 year;\n24. History of psychiatric illnesses;\n25. History of any other uncontrolled chronic or acute concomitant disease which, in the Investigator's opinion, would contraindicate study participation or confound interpretation of the results;\n26. Patient not capable of understanding or not willing to adhere to the study visit schedules and other protocol requirements;\n27. Participation in any other interventional clinical study within 30 days prior to the screening visit.",{"count":180,"type":20},6,[182],"EARLY_PHASE1","The objectives of this study are to evaluate the efficacy and safety of crofelemer treatment in adults affected by Short Bowel Syndrome (SBS) with an ileostomy on parenteral support (PS) in reducing output or PS needs. Crofelemer will be provided as a powder three times daily for 12 weeks and a 4 week follow up. .",[26],[186],"SBS",{"date":164,"type":33},{"date":189,"type":33},"2025-03-03",{"date":191,"type":20},"2026-02-01",{"name":193,"class":171},"Lindsey Russell, MD",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":201,"maxAge":17,"enrollmentInfo":202,"targetDuration":4,"studyType":21,"phases":204,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":172},"100326501","a-90-day-phase-3open-labeled-exploratory-study-of-relizorb-100326501","NCT03530852","A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB","A 90 Day, Phase 3, Open Labeled Exploratory Study of RELiZORB to Evaluate Safety, Tolerability, and Nutrient Absorption in Children With Short Bowel Syndrome Who Are Dependent on Parenteral Nutrition","Inclusion Criteria:\n\n1. Male or female patients, ages 2 years to 18 years, inclusive.\n2. Diagnosed with SBS, as determined by medical history and PN dependence (i.e. need for PN for \\>60 days after intestinal resection or a bowel length \\\u003C25% of expected).\n3. Congenital or acquired gastrointestinal disease requiring surgical intervention that has occurred at least 3 months prior to screening.\n4. Patient is on parenteral lipid and at least 30% of daily caloric and fluid intake has been provided by PN for a least 6 months prior to screening\n5. Stable PN nutrition requirement, determined by less than 5% reduction in PN nutrition calories for at least 1 month prior to screening, or at the discretion of the investigator.\n6. Screening direct bilirubin that is in the normal range for age and is not determined to be clinically significant by the investigator.\n7. Subject has an existing feeding tube, is receiving enteral nutrition via a pump at a rate\\>10ml\u002Fhr but \\\u003C120ml\u002Fhr, and is able to tolerate at least 10 ml\u002Fkg\u002Fday enteral nutrition.\n8. Stable enteral nutrition requirement with no change in formula composition or rate for at least 1 month prior to screening.\n9. The parent or legal guardian of the patient is able to read, understand, and is willing to provide informed consent (and assent, if applicable).\n10. The patient (if assent is applicable) or parent or legal guardian of the patient is able to understand the requirements of the study and is willing to bring the patient to all clinic visits and complete all study related procedures (as determined by the investigator).\n\nA parent or legal guardian is willing to provide written authorization for the use and disclosure of protected health information.\n\nExclusion criteria:\n\n1. Other causes of chronic liver disease other than SBS (i.e., hepatitis C, cystic fibrosis, biliary atresia, alpha 1 anti-trypsin deficiency, and Alagille syndrome).\n2. The patient has had a bowel lengthening procedure, including but not limited to, a STEP procedure.\n3. Any serum triglyceride concentration \\>400 mg\u002FdL at screening.\n4. Pancreatic insufficiency as defined as the use of pancreatic enzymes within 30 days prior to screening.\n5. Evidence of untreated intestinal obstruction or active stenosis, as determined by the investigator.\n6. Unstable absorption due to cystic fibrosis or known DNA abnormalities (i.e., familial adenomatous polyposis, Fanconi syndrome) as determined by the investigator.\n7. History of microvillus inclusion disease, as determined by medical history.\n8. Severe known dysmotility syndrome (i.e., pseudo-obstruction, gastroschisis-related motility disorders), as determined by the investigator.\n9. Initiation of teduglutide or other GLP-2 analogues within 6 months of screening\n10. Use of growth hormone, or supplemental glutamine within 3 months prior to screening.\n11. Use of cisapride within 30 days prior to screening.\n12. Active clinically significant pancreatic or biliary disease, as determined by the investigator.\n13. Patients are receiving formulas that are not compatible with the RELiZORB cartridge (example, insoluble fiber-containing formulas)\n14. Determined by the investigator to be unsuitable for participation for any reason.","2 Years",{"count":203,"type":20},32,[205],"NA","Children with inadequate intestinal absorption due to loss of large amounts of small bowel require intravenous nutrition (feeding through the vein) to sustain hydration and nutrition to avoid starvation and dehydration; however, intravenous (IV) nutrition can lead to complications including liver failure. Tube feeding directly to the small intestine avoids the complications of IV nutrition, but fats are not fully digestible due to inadequate bowel function. We propose to predigest the fat using a small cartridge attached to the feeding tube to allow for rapid absorption with the possibility of reducing or eliminating the need for intravenous nutrition",[26,208],"Malabsorption","2025-12-15",{"date":211,"type":33},"2025-12-17",{"date":213,"type":33},"2018-11-21",{"date":215,"type":20},"2028-09-30",{"name":217,"class":171},"Boston Children's Hospital",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":16,"minAge":224,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":21,"phases":228,"briefSummary":229,"conditions":230,"keywords":231,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":180},"100480390","a-feasibility-study-to-evaluate-safety-and-probable-benefit-of-the-eclipse-xl1-system-for-distraction-enterogenesis-in-adult-and-pediatric-patients-with-short-bowel-syndrome-100480390","NCT05535361","A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome","Inclusion Criteria:\n\n* Subject has short bowel syndrome, defined as 50% or less of expected bowel length based on subject age and\u002For height, and measured at the time of the subject's prior intestinal resection.\n* Minimum residual bowel length of 3 cm.\n* Male or female patients aged 3 mo to 65 years inclusive\n* The subject, parent or legal guardian of the subject is able to read, understand, and is willing to provide informed consent.\n* The subject or parent or legal guardian of the patient is able to understand the requirements of the study and is willing to bring the subject to all clinic visits and complete all study related procedures (as determined by the investigator).\n\nExclusion Criteria:\n\n* Ultra-short bowel syndrome defined as less than 3 cm of bowel length.\n* Diagnosed Inflammatory bowel disease-unclassified (not Crohn's or ulcerative colitis)\n* Evidence of active or prior Crohn's disease.\n* Primary intestinal failure (i.e., without loss or resection of intestinal tissue).\n* Coagulopathy, as defined by INR \\> 1.4 or platelets \\\u003C 100.\n* Known immunocompromised status including, but not limited to, individuals who have undergone organ transplantation, chemotherapy or radiotherapy within the past 12 months, who have clinically significant leukopenia, who are positive for the human immunodeficiency virus (HIV) or whose immune status makes the subject a poor candidate for clinical trial participation in the opinion of the Investigator.\n* Subject is determined by the investigator to be unsuitable for participation in this trial for any reason.","3 Months","65 Years",{"count":227,"type":20},40,[205],"A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients with Short Bowel Syndrome",[26],[232,233,234,235,236,237],"short bowel syndrome","intestinal failure","Necrotizing enterocolitis","short gut","intestinal volvulus","intestinal atresia","2025-10-03",{"date":240,"type":33},"2025-10-08",{"date":242,"type":33},"2025-09-15",{"date":244,"type":20},"2028-06-30",{"name":246,"class":171},"Eclipse Regenesis, Inc.",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":256,"conditions":257,"keywords":259,"overallStatus":264,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":172},"100608780","effect-of-parenteral-support-on-fibroscan-in-short-bowel-syndrome-100608780","NCT07206004","Effect of Parenteral Support on FibroScan in Short Bowel Syndrome","Effect of Parenteral Nutrition\u002FFluids on FibroScan Results in Patients With Short Bowel Syndrome","Inclusion Criteria:\n\n* Adult patients (≥18 years) with short bowel syndrome with capacity to give consent\n* Patients receiving regular PS (≥4 days\u002Fweek and ≥10 liters\u002Fweek)\n* Stable clinical condition\n\nExclusion Criteria:\n\n* Known liver cirrhosis\n* Active infection, severe dehydration, or electrolyte disturbances\n* Pregnancy\n* Receiving IV fluids or medications on study day\n* Tapered infusion rate prior to disconnection",{"count":255,"type":20},20,"Home Parenteral Support (HPS) is a life-sustaining treatment for patients with short bowel syndrome and intestinal failure. This study aims to investigate how administration of parenteral support affects FibroScan results in order to determine optimal timing of liver assessment in this patient population.",[26,107,258],"Liver Diseases",[260,261,262,233,263],"FibroScan","transient elastography","parenteral nutrition","hepatic fibrosis","NOT_YET_RECRUITING","2025-09-25",{"date":238,"type":33},{"date":268,"type":20},"2026-02",{"date":270,"type":20},"2027-08",{"name":272,"class":171},"Rigshospitalet, Denmark",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":281,"targetDuration":283,"studyType":157,"phases":4,"briefSummary":284,"conditions":285,"keywords":628,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":671,"lastUpdatePostDateStruct":672,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":679},"100193378","rare-disease-patient-registry--natural-history-study---coordination-of-rare-diseases-at-sanford-100193378","NCT01793168","Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford","Coordination of Rare Diseases at Sanford","CoRDS","Inclusion Criteria:\n\n* Diagnosis of a rare disease, a disease of unknown prevalence, undiagnosed or an unaffected carrier of a rare\u002Funcommon disease\n\nExclusion Criteria:\n\n* Diagnosis of a disease which is not rare",{"count":282,"type":20},20000,"100 Years","CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, individuals and researchers to help in the advancement of research in over 7,000 rare diseases. The registry is free for patients to enroll and researchers to access. Visit sanfordresearch.org\u002FCoRDS to enroll.",[286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404,405,406,407,408,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496,497,498,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,524,525,526,527,528,529,530,531,532,533,534,535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,26,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592,593,594,595,596,597,598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627],"Rare Disorders","Undiagnosed Disorders","Disorders of Unknown Prevalence","Cornelia De Lange Syndrome","Prenatal Benign Hypophosphatasia","Perinatal Lethal Hypophosphatasia","Odontohypophosphatasia","Adult Hypophosphatasia","Childhood-onset Hypophosphatasia","Infantile Hypophosphatasia","Hypophosphatasia","Kabuki Syndrome","Bohring-Opitz Syndrome","Narcolepsy Without Cataplexy","Narcolepsy-cataplexy","Hypersomnolence Disorder","Idiopathic Hypersomnia Without Long Sleep Time","Idiopathic Hypersomnia With Long Sleep Time","Idiopathic Hypersomnia","Kleine-Levin Syndrome","Kawasaki Disease","Leiomyosarcoma","Leiomyosarcoma of the Corpus Uteri","Leiomyosarcoma of the Cervix Uteri","Leiomyosarcoma of Small Intestine","Acquired Myasthenia Gravis","Addison Disease","Hyperacusis (Hyperacousis)","Juvenile Myasthenia Gravis","Transient Neonatal Myasthenia Gravis","Williams Syndrome","Lyme Disease","Myasthenia Gravis","Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome)","Isolated Klippel-Feil Syndrome","Frasier Syndrome","Denys-Drash Syndrome","Beckwith-Wiedemann Syndrome","Emanuel Syndrome","Isolated Aniridia","Axenfeld-Rieger Syndrome","Aniridia-intellectual Disability Syndrome","Aniridia - Renal Agenesis - Psychomotor Retardation","Aniridia - Ptosis - Intellectual Disability - Familial Obesity","Aniridia - Cerebellar Ataxia - Intellectual Disability","Aniridia - Absent Patella","Aniridia","Peters Anomaly - Cataract","Peters Anomaly","Potocki-Shaffer Syndrome","Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11","Silver-Russell Syndrome Due to Imprinting Defect of 11p15","Silver-Russell Syndrome Due to 11p15 Microduplication","Syndromic Aniridia","WAGR Syndrome","Wolf-Hirschhorn Syndrome","4p16.3 Microduplication Syndrome","4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome","Autosomal Recessive Stickler Syndrome","Stickler Syndrome Type 2","Stickler Syndrome Type 1","Stickler Syndrome","Mucolipidosis Type 4","X-linked Spinocerebellar Ataxia Type 4","X-linked Spinocerebellar Ataxia Type 3","X-linked Intellectual Disability - Ataxia - Apraxia","X-linked Progressive Cerebellar Ataxia","X-linked Non Progressive Cerebellar Ataxia","X-linked Cerebellar Ataxia","Vitamin B12 Deficiency Ataxia","Toxic Exposure Ataxia","Unclassified Autosomal Dominant Spinocerebellar Ataxia","Thyroid Antibody Ataxia","Sporadic Adult-onset Ataxia of Unknown Etiology","Spinocerebellar Ataxia With Oculomotor Anomaly","Spinocerebellar Ataxia With Epilepsy","Spinocerebellar Ataxia With Axonal Neuropathy Type 2","Spinocerebellar Ataxia Type 8","Spinocerebellar Ataxia Type 7","Spinocerebellar Ataxia Type 6","Spinocerebellar Ataxia Type 5","Spinocerebellar Ataxia Type 4","Spinocerebellar Ataxia Type 37","Spinocerebellar Ataxia Type 36","Spinocerebellar Ataxia Type 35","Spinocerebellar Ataxia Type 34","Spinocerebellar Ataxia Type 32","Spinocerebellar Ataxia Type 31","Spinocerebellar Ataxia Type 30","Spinocerebellar Ataxia Type 3","Spinocerebellar Ataxia Type 29","Spinocerebellar Ataxia Type 28","Spinocerebellar Ataxia Type 27","Spinocerebellar Ataxia Type 26","Spinocerebellar Ataxia Type 25","Spinocerebellar Ataxia Type 23","Spinocerebellar Ataxia Type 22","Spinocerebellar Ataxia Type 21","Spinocerebellar Ataxia Type 20","Spinocerebellar Ataxia Type 2","Spinocerebellar Ataxia Type 19\u002F22","Spinocerebellar Ataxia Type 18","Spinocerebellar Ataxia Type 17","Spinocerebellar Ataxia Type 16","Spinocerebellar Ataxia Type 15\u002F16","Spinocerebellar Ataxia Type 14","Spinocerebellar Ataxia Type 13","Spinocerebellar Ataxia Type 12","Spinocerebellar Ataxia Type 11","Spinocerebellar Ataxia Type 10","Spinocerebellar Ataxia Type 1 With Axonal Neuropathy","Spinocerebellar Ataxia Type 1","Spinocerebellar Ataxia - Unknown","Spinocerebellar Ataxia - Dysmorphism","Non Progressive Epilepsy and\u002For Ataxia With Myoclonus as a Major Feature","Spasticity-ataxia-gait Anomalies Syndrome","Spastic Ataxia With Congenital Miosis","Spastic Ataxia - Corneal Dystrophy","Spastic Ataxia","Rare Hereditary Ataxia","Rare Ataxia","Recessive Mitochondrial Ataxia Syndrome","Progressive Epilepsy and\u002For Ataxia With Myoclonus as a Major Feature","Posterior Column Ataxia - Retinitis Pigmentosa","Post-Stroke Ataxia","Post-Head Injury Ataxia","Post Vaccination Ataxia","Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract","Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus","Non-hereditary Degenerative Ataxia","Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity","Olivopontocerebellar Atrophy - Deafness","NARP Syndrome","Myoclonus - Cerebellar Ataxia - Deafness","Multiple System Atrophy, Parkinsonian Type","Multiple System Atrophy, Cerebellar Type","Multiple System Atrophy","Maternally-inherited Leigh Syndrome","Machado-Joseph Disease Type 3","Machado-Joseph Disease Type 2","Machado-Joseph Disease Type 1","Leigh Syndrome","Late-onset Ataxia With Dementia","Infection or Post Infection Ataxia","GAD Ataxia","Hereditary Episodic Ataxia","Gliadin\u002FGluten Ataxia","Friedreich Ataxia","Fragile X-associated Tremor\u002FAtaxia Syndrome","Familial Paroxysmal Ataxia","Exposure to Medications Ataxia","Episodic Ataxia With Slurred Speech","Episodic Ataxia Unknown Type","Episodic Ataxia Type 7","Episodic Ataxia Type 6","Episodic Ataxia Type 5","Episodic Ataxia Type 4","Episodic Ataxia Type 3","Episodic Ataxia Type 1","Epilepsy and\u002For Ataxia With Myoclonus as Major Feature","Early-onset Spastic Ataxia-neuropathy Syndrome","Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity","Early-onset Cerebellar Ataxia With Retained Tendon Reflexes","Early-onset Ataxia With Dementia","Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia","Dilated Cardiomyopathy With Ataxia","Cataract - Ataxia - Deafness","Cerebellar Ataxia, Cayman Type","Cerebellar Ataxia With Peripheral Neuropathy","Cerebellar Ataxia - Hypogonadism","Cerebellar Ataxia - Ectodermal Dysplasia","Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss","Brain Tumor Ataxia","Brachydactyly - Nystagmus - Cerebellar Ataxia","Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia","Autosomal Recessive Syndromic Cerebellar Ataxia","Autosomal Recessive Spastic Ataxia With Leukoencephalopathy","Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay","Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria","Autosomal Recessive Spastic Ataxia","Autosomal Recessive Metabolic Cerebellar Ataxia","Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine","Autosomal Recessive Ataxia, Beauce Type","Autosomal Recessive Ataxia Due to Ubiquinone Deficiency","Autosomal Recessive Ataxia Due to PEX10 Deficiency","Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia","Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency","Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency","Autosomal Recessive Congenital Cerebellar Ataxia","Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome","Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency","Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency","Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency","Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome","Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity","Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency","Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect","Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion","Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation","Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness","Autosomal Recessive Cerebellar Ataxia","Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly","Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation","Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy","Autosomal Dominant Spastic Ataxia Type 1","Autosomal Dominant Spastic Ataxia","Autosomal Dominant Optic Atrophy","Ataxia-telangiectasia Variant","Ataxia-telangiectasia","Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy","Autosomal Dominant Cerebellar Ataxia Type 4","Autosomal Dominant Cerebellar Ataxia Type 3","Autosomal Dominant Cerebellar Ataxia Type 2","Autosomal Dominant Cerebellar Ataxia Type 1","Autosomal Dominant Cerebellar Ataxia","Ataxia-telangiectasia-like Disorder","Ataxia With Vitamin E Deficiency","Ataxia With Dementia","Ataxia - Oculomotor Apraxia Type 1","Ataxia - Other","Ataxia - Genetic Diagnosis - Unknown","Acquired Ataxia","Adult-onset Autosomal Recessive Cerebellar Ataxia","Alcohol Related Ataxia","Multiple Endocrine Neoplasia","Multiple Endocrine Neoplasia Type II","Multiple Endocrine Neoplasia Type 1","Multiple Endocrine Neoplasia Type 2","Multiple Endocrine Neoplasia, Type IV","Multiple Endocrine Neoplasia, Type 3","Multiple Endocrine Neoplasia (MEN) Syndrome","Multiple Endocrine Neoplasia Type 2B","Multiple Endocrine Neoplasia Type 2A","Atypical Hemolytic Uremic Syndrome","Atypical HUS","Wiedemann-Steiner Syndrome","Breast Implant-Associated Anaplastic Large Cell Lymphoma","Autoimmune\u002FInflammatory Syndrome Induced by Adjuvants (ASIA)","Hemophagocytic Lymphohistiocytosis","Behcet's Disease","Alagille Syndrome","Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD)","Lowe Syndrome","Pitt Hopkins Syndrome","1p36 Deletion Syndrome","Jansen Type Metaphyseal Chondrodysplasia","Cockayne Syndrome","Chronic Recurrent Multifocal Osteomyelitis","CRMO","Malan Syndrome","Hereditary Sensory and Autonomic Neuropathy Type Ie","VCP Disease","Hypnic Jerking","Sleep Myoclonus","Mollaret Meningitis","Recurrent Viral Meningitis","CRB1","Leber Congenital Amaurosis","Retinitis Pigmentosa","Rare Retinal Disorder","KCNMA1-Channelopathy","Primary Biliary Cirrhosis","ZMYND11","Transient Global Amnesia","Glycogen Storage Disease","Alstrom Syndrome","White Sutton Syndrome","DNM1","EIEE31","Myhre Syndrome","Recurrent Respiratory Papillomatosis","Laryngeal Papillomatosis","Tracheal Papillomatosis","Refsum Disease","Nicolaides Baraitser Syndrome","Leukodystrophy","Tango2","Cauda Equina Syndrome","Rare Gastrointestinal Disorders","Achalasia-Addisonian Syndrome","Achalasia Cardia","Achalasia Icrocephaly Syndrome","Anal Fistula","Congenital Sucrase-Isomaltase Deficiency","Eosinophilic Gastroenteritis","Idiopathic Gastroparesis","Hirschsprung Disease","Rare Inflammatory Bowel Disease","Intestinal Pseudo-Obstruction","Scleroderma","Sacral Agenesis","Sacral Agenesis Syndrome","Caudal Regression","Scheuermann Disease","SMC1A Truncated Mutations (Causing Loss of Gene Function)","Cystinosis","Juvenile Nephropathic Cystinosis","Nephropathic Cystinosis","Kennedy Disease","Spinal Bulbar Muscular Atrophy","Warburg Micro Syndrome","Mucolipidoses","Mitochondrial Diseases","Mitochondrial Aminoacyl-tRNA Synthetases","Mt-aaRS Disorders","Hypertrophic Olivary Degeneration","Non-Ketotic Hyperglycinemia","Fish Odor Syndrome","Halitosis","Isolated Congenital Asplenia","Lambert Eaton (LEMS)","Biliary Atresia","STAG1 Gene Mutation","Coffin Lowry Syndrome","Borjeson-Forssman-Lehman Syndrome","Blau Syndrome","Arginase 1 Deficiency","HSPB8 Myopathy","Beta-Mannosidosis","TBX4 Syndrome","DHDDS Gene Mutations","MAND-MBD5-Associated Neurodevelopmental Disorder","Constitutional Mismatch Repair Deficiency (CMMRD)","SPATA5 Disorder","SPATA5L1 Related Disorder","Acrodysostosis","Multi-systematic Smooth Muscle Dysfunction Syndrome","CRELD1 (Cysteine Rich With EGF Like Domains 1)","GNB1 Syndrome","Pyruvate Dehydrogenase Complex Deficiency Disease","Beta Mannosidosis","Kbg Syndrome","Labrune Syndrome","Metachromatic Leukodystrophy (MLD)","Moyamoya Disease","OPHN1 Syndrome","Oculopharyngeal Muscular Dystrophy (OPMD)","TUBB3 Mutation","WOREE (WWOX-related Epileptic Encephalopathy","SCAR12","Skraban-Deardorff Syndrome","Hereditary Myopathy With Early Respiratory Failure",[629,630,631,632,633,340,634,635,347,636,306,637,638,639,510,519,640,641,297,642,643,305,644,307,645,296,646,647,522,648,649,525,526,650,528,529,651,652,532,653,654,655,581,656,657,658,659,660,661,662,586,663,664,665,591,592,666,667,668,669,670],"Rare Diseases","Neglected Diseases","Orphan Diseases","Rare Disease Research","Registries","Ataxia","Cornelia de Lange Syndrome","Ataxia Telangiectasia","Batten Disease","Mucolipidosis IV","Klippel-Feil Syndrome","Undiagnosed","Uncommon Disease","Hypersomnia","Hyperacusis","Marinesco-Sjogren Syndrome","4p-\u002FWolf-Hirschhorn Syndrome","Narcolepsy","Wiedermann-Steiner Syndrome","Autoimmune\u002Finflammatory Syndrome Induced by Adjuvants (ASIA)","Hemophagocytic Lymphohistiocytosis (HLH)","Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia (IBMPFD)","1p36 deletion syndrome","Jansen metaphyseal chondrodysplasia","Chronic recurrent multifocal osteomyelitis (CRMO)","Malan syndrome","Hereditary Sensory and Autonomic Neuropathy","Juvenile nephropathic cystinosis","Nephropathic infantile cystinosis","Ocular cystinosis","Kennedy disease","Spinal Bulbar Muscular Atrophy (SBMA)","SMC1A Truncated Mutations (causing loss of gene function)","Leigh syndrome","Mucolipidosis","Mitochondrial aminoacyl-tRNA synthetases (Mt-aaRS Disorders)","Shine Syndrome","Intestinal Bromhidrosis Syndrome","Fish odor syndrome","Autosomal recessive extra oral halitosis","CACNA1H mutation","Dimethylglycine dehydrogenase deficiency","2025-05-22",{"date":65,"type":33},{"date":674,"type":33},"2010-07",{"date":676,"type":20},"2100-12",{"name":678,"class":171},"Sanford Health",2,{"id":681,"slug":682,"hasResults":11,"nctId":683,"briefTitle":684,"officialTitle":685,"acronym":686,"eligibilityCriteria":687,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":688,"targetDuration":4,"studyType":21,"phases":690,"briefSummary":692,"conditions":693,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":695,"lastUpdatePostDateStruct":696,"startDateStruct":698,"completionDateStruct":700,"leadSponsor":702,"locationsCount":172},"100462505","phase-1-absorption-of-antibiotics-with-high-oral-bioavailability-in-short-bowel-syndrome-100462505","NCT05302531","Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome","Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome : a Monocentric Pilot Study","GRAAL","Inclusion Criteria:\n\n* Short bowel syndrome\n* Treated for a documented infection with antibiogram by amoxicillin (+\u002F- clavulanic acid)or ofloxacin or levofloxacin or sulfamethoxazole\u002Ftrimethoprim\n* Hospitalized in the Nutritional Assistant Unit or the Infectiology Unit of the Regional University Hospital of Nancy\n* Affiliated to a social security system\n* Having received an physical examination before entering study\n* Having received full information regarding the study organization and having signed the informed consent\n\nExclusion Criteria:\n\n* Patient at risk of worsening their oral absorption abilities during study\n* Patient requiring dialysis\n* Women of childbearing age without efficient birth control\n* Allergy to any of the drugs tested\n* Person concerned by Articles L. 1121-5, L. 1121-7 et L1121-8 of the Code of public health\n* Person deprived of liberty or person undergoing psychiatric care pursuant to articles L. 3212-1 et L. 3213-1",{"count":689,"type":20},10,[691],"PHASE1","The purpose of this study is to assess the drug absorption of oral antibiotics in patients with short bowel syndrome.",[26,694],"Infection, Bacterial","2024-08-28",{"date":697,"type":33},"2024-08-29",{"date":699,"type":33},"2022-12-09",{"date":701,"type":20},"2025-02",{"name":703,"class":171},"Central Hospital, Nancy, France"]